Heterogeneity of treatment response in bronchiectasis clinical trials
O. Sibila (Barcelona, Spain), E. Laserna (Mollet del Valles, Spain), A. Shoemark (Dundee, United Kingdom), D. Bilton (London, United Kingdom), M. Crichton (Dundee, United Kingdom), A. De Soyza (Newcastle, United Kingdom), W. Boersma (Alkmaar, Netherlands), J. Altenburg (Amsterdam, Netherlands), J. Chalmers (Dundee, United Kingdom)
Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria
Disease area: Airway diseases, Respiratory infections
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. Sibila (Barcelona, Spain), E. Laserna (Mollet del Valles, Spain), A. Shoemark (Dundee, United Kingdom), D. Bilton (London, United Kingdom), M. Crichton (Dundee, United Kingdom), A. De Soyza (Newcastle, United Kingdom), W. Boersma (Alkmaar, Netherlands), J. Altenburg (Amsterdam, Netherlands), J. Chalmers (Dundee, United Kingdom). Heterogeneity of treatment response in bronchiectasis clinical trials. 3332
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: